We use cookies for a better user experience. Read our Privacy Policy

I Agree

Schizophrenia Drugs Market

Schizophrenia Drugs Market (Drug Class: First Generation Drugs, Second Generation Drugs, and Third Generation Drugs; Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Companies Increase Focus on Second-generation Drugs with Polypharmacology Approach

Several doctors and healthcare providers are adopting the methods of polypharmacology to develop new drugs for mental disorders. These methods are providing better outcomes in patients as compared to single-target drugs in the schizophrenia drugs market.

Likewise, multi-target drugs are emerging as an effective alternative to treat polygenic diseases, including schizophrenia. As such, the second-generation drugs market is estimated to reach ~US$ 11.1 billion by the year 2027; the highest amongst all drug classes in the schizophrenia drugs landscape. These second-generation drugs, i.e. atypical antipsychotics, target a number of aminergic G-protein coupled receptors (GPCRs) to treat complex pathomechanisms of schizophrenia.

Pharmaceutical companies are increasing research & development related to the schizophrenia drugs market to develop drugs that are beyond the dopaminergic hypothesis of schizophrenia and beyond monoamine G protein coupled receptors (GPCRs). They are increasing their production capacities of dopamine antagonists and drugs meant to effectively control the symptoms of schizophrenia and improve patient quality of life. Manufacturers in the schizophrenia drugs market are also turning towards other second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients.

schizophrenia drugs market infographic

To understand how our report can bring difference to your business strategy, Ask for a brochure

High-content Single-cell Screenings Serve as a Strategic Alternative

There is the growing need for improved schizophrenia drugs, as psychiatric disorders lead to disorders of the whole body. That is why, healthcare companies are innovating on live cellular function as a model to treat schizophrenia. Manufacturers in the schizophrenia drugs market are using high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs. This drug 'repurposing' strategy serves as a cost-effective and time-saving alternative for the development of new schizophrenia drugs that can be supplied to small-scale clinics and other healthcare providers.

The live cellular function model helps manufacturers develop new potential drugs at competitive costs, and acts as an efficient alternative to develop the drugs in a significantly less amount of time. The high-content single-cell screening process helps companies test existing psychiatric treatments on patient blood cells and predict the effectiveness of the new schizophrenia drug, depending upon the health condition of each individual.

This first-of-its-kind process will help healthcare companies overcome the limitations of first-line treatments, as these treatments have been performing poorly in most patients.

Request a sample to get extensive insights into the Schizophrenia Drugs Market

Study of Live Blood Cells Gives Rise to Potential Schizophrenia Drugs

One of the major challenges that restricts healthcare companies from developing novel drugs for the schizophrenia drugs market is the lack of sample-based tests. Since doctors cannot take brain tissue samples from patients like they do in a biopsy on a cancer tumor elsewhere in the body, it is challenging for researchers to study the root causes of schizophrenia. This becomes a hurdle for doctors and researchers as to what to target in order to design novel neuropsychiatric drugs. As such, healthcare companies are collaborating with doctors and researchers to study the live blood cells of patients with mental health disorders. These blood cells help researchers identify potential targets for drug discovery.

Companies are increasing focus on the study of human blood cells, as these cells are closely associated with the central nervous system. This makes blood cells an ideal environment to test potential new drugs.

schizophrenia drugs market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Schizophrenia Drugs Market” 

Analysts’ Viewpoint

The schizophrenia drugs market is expected to grow the fastest in Asia Pacific on an account of the demand for less-invasive oral drugs that are anticipated to reach ~US$ 10.8 billion by 2027. Healthcare companies are increasing research on primary cells from patients to gain high success rates in the discovery of effective drugs. They are also innovating on antipsychotic drugs, as these drugs provide a range of tools to explore brain function in health and mental disorders. However, antipsychotic drugs have a high risk of disrupting the extrapyramidal function in patients. Also, these drugs do not have enough clinical evidence to prove their effectiveness in the development of new compounds in drugs.

As such, healthcare companies are increasing research & development to closely understand the effects of antipsychotic drugs on the central dopamine homeostasis of patients. Companies operating in the schizophrenia drugs market should focus on new models of preventive treatments of schizophrenia, such as the animal model and stem cell technology, for improved schizophrenia drug screenings.

Schizophrenia Drugs Market: Overview

  • Rise in the prevalence of schizophrenia, approvals for additional indications, and launch of new schizophrenia drugs are driving the schizophrenia drugs market.
  • The number of patients that are suffering from schizophrenia has been increasing across the world. Moreover, rise in the launch of new schizophrenia drugs in various countries is fueling the growth of the global schizophrenia market.
  • These factors are estimated to boost the global schizophrenia drugs market during the forecast period. The schizophrenia drugs market was valued at ~US$ 11.2 Bn in 2018, and is projected to reach ~US$ 15.5 Bn by 2027, expanding at a CAGR of ~4% from 2019 to 2027.

Schizophrenia Drugs Market: Key Trends

  • The market for schizophrenia drugs is an established market, owing to the high demand for schizophrenia drugs in developed as well as developing countries. Additionally, leading market players in the schizophrenia drugs market are engaged in the development of innovative products.
  • Based on drug class, the global schizophrenia drugs market has been categorized into first generation drugs, second generation drugs, and third generation drugs. The second generation drugs segment held a major share of the global schizophrenia drugs market in 2018, owing to their low risk of neurological side effects as compared to first generation of schizophrenia drugs.
  • In terms of route of administration, the global schizophrenia drugs market has been segregated into oral and injectable. The oral segment dominated the global schizophrenia drugs market, owing to easy accessibility to oral drugs, their non-invasive nature, and high preference by patients.
  • The number of people affected by depression has been rising all across the world. According to the WHO, more than 300 million people suffer from depression and over 800,000 people commit suicide every year. Depression is the second leading cause of death in 15–29 year olds.
  • Increase in the number of launches of new schizophrenia drugs in various countries is fueling the global schizophrenia drugs market.
    • In 2015, Otsuka Holdings Co., Ltd. announced the launch of Rexulti in the U.S. In April 2017, the drug was also launched in Canada. 

Schizophrenia Drugs Market: Competition

  • The report provides the company profiles that includes key information about the major players in the schizophrenia drugs market.
  • Each of these players have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segment, and recent developments.
  • The schizophrenia drugs market is highly consolidated, owing to a small number of market players selling approved drugs for schizophrenia.
  • Janssen Global Services, LLC (Johnson & Johnson), ALLERGAN, Pfizer Inc., and Otsuka Holdings Co., Ltd. are major players operating in the global schizophrenia drugs market. 

FDA Approval and Product Expansion

  • In January 2018, Otsuka Pharmaceutical Co., Ltd. announced that it received regulatory approval for the manufacture and sales of Rexulti tablets (generic name - brexpiprazole) in Japan. Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and as an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.
  • In January 2018, Janssen Global Services, LLC received FDA approval for INVEGA SUSTENNA (paliperidone palmitate), a once-monthly schizophrenia treatment drug. This is the first and only antipsychotic drug to have U.S. Food and Drug Administration (FDA) approval.
  • In November 2017, ALLERGAN received FDA approval for use of VRAYLAR (cariprazine) for the treatment of schizophrenia. VRAYLAR is an oral, once-daily atypical antipsychotic drug approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar disorder, with a recommended dose range of 3 to 6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5 to 6 mg/day. 

Mergers & Acquisitions to Strengthen Market Position

  • In February 2015, Pfizer, Inc. and Hospira, Inc. (a leading player in infusion technologies and injectable drugs) signed a merger agreement. Under the agreement, Pfizer would acquire Hospira for a total transaction value of ~US$ 17 Bn. This complementary merger would help in expanding the company’s portfolio of sterile injectable pharmaceuticals and biosimilars.

Global Schizophrenia Drugs Market – Segmentation

Drug Class

First Generation Drugs

Second Generation Drugs

Third Generation Drugs

Route of Administration

Injectable

Oral

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Schizophrenia Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of schizophrenia drugs market?

Schizophrenia drugs market is projected to reach ~US$ 15.5 Bn by 2027

What is the anticipated CAGR of the schizophrenia drugs market in the forecast period?

Schizophrenia drugs market expand at a CAGR of ~4% from 2019 to 2027

What are the key driving factors for the growth of the schizophrenia drugs market?

Schizophrenia drugs market is driven by rise in the prevalence of schizophrenia and launch of new schizophrenia drugs

Which is the rising prominent segment in the schizophrenia drugs market?

The second generation drugs segment dominated the global schizophrenia drugs market, owing to their low risk of neurological side effects

Who are the key players in the schizophrenia drugs market?

Key players in the schizophrenia drugs market include Janssen Global Services, LLC (Johnson & Johnson), ALLERGAN, Pfizer Inc., and Otsuka Holdings Co., Ltd., Pfizer, Inc. and Hospira, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Schizophrenia Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Schizophrenia Drugs Introduction

        4.1.2. Market Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027

        4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast

5. Key Insights

    5.1. Pipeline Analysis: Schizophrenia Drugs

    5.2. Value Chain Analysis

    5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027

6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class 

    6.1. Introduction & Definitions

    6.2. Key Findings / Developments

    6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        6.3.1. First Generation Drugs

        6.3.2. Second Generation Drugs

        6.3.3. Third Generation Drugs

    6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class 

7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration 

    7.1. Introduction & Definitions

    7.2. Key Findings / Developments

    7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        7.3.1. Injectable

        7.3.2. Oral

    7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration 

8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Schizophrenia Drugs Market Attractiveness, by Region

9. North America Schizophrenia Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        9.2.1. First Generation Drugs

        9.2.2. Second Generation Drugs

        9.2.3. Third Generation Drugs

    9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        9.3.1. Injectable

        9.3.2. Oral

    9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Schizophrenia Drugs Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By Route of Administration 

        9.5.3. By Country

10. Europe Schizophrenia Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.2.1. First Generation Drugs

        10.2.2. Second Generation Drugs

        10.2.3. Third Generation Drugs

    10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        10.3.1. Injectable

        10.3.2. Oral

    10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By Route of Administration 

        10.5.3. By Country/Sub-region

11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.2.1. First Generation Drugs

        11.2.2. Second Generation Drugs

        11.2.3. Third Generation Drugs

    11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        11.3.1. Injectable

        11.3.2. Oral

    11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. India

        11.4.3. Japan

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By Route of Administration 

        11.5.3. By Country/Sub-region

12. Latin America Schizophrenia Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.2.1. First Generation Drugs

        12.2.2. Second Generation Drugs

        12.2.3. Third Generation Drugs

    12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        12.3.1. Injectable

        12.3.2. Oral

    12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Route of Administration 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.2.1. First Generation Drugs

        13.2.2. Second Generation Drugs

        13.2.3. Third Generation Drugs

    13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        13.3.1. Injectable

        13.3.2. Oral

    13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC 

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By Route of Administration 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)

    14.2. Company Profiles

        14.2.1. Allergan

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Financial Overview

            14.2.1.3. Product Portfolio

            14.2.1.4. SWOT Analysis 

            14.2.1.5. Strategic Overview

        14.2.2. Otsuka Holdings Co., Ltd

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Financial Overview

            14.2.2.3. Product Portfolio

            14.2.2.4. SWOT Analysis 

            14.2.2.5. Strategic Overview

        14.2.3. Janssen Pharmaceutica (Johnson & Johnson)

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.3.2. Financial Overview

            14.2.3.3. Product Portfolio

            14.2.3.4. SWOT Analysis 

            14.2.3.5. Strategic Overview

        14.2.4. Pfizer Inc.

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.4.2. Financial Overview

            14.2.4.3. Product Portfolio

            14.2.4.4. SWOT Analysis 

            14.2.4.5. Strategic Overview

        14.2.5. Maynepharma

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.5.2. Financial Overview

            14.2.5.3. Product Portfolio

            14.2.5.4. SWOT Analysis 

            14.2.5.5. Strategic Overview

        14.2.6. Vanda Pharmaceuticals Inc.

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.6.2. Financial Overview

            14.2.6.3. Product Portfolio

            14.2.6.4. SWOT Analysis 

            14.2.6.5. Strategic Overview

        14.2.7. Sumitomo Dainippon Pharma

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.7.2. Financial Overview

            14.2.7.3. Product Portfolio

            14.2.7.4. SWOT Analysis 

            14.2.7.5. Strategic Overview

        14.2.8. Eli Lilly & Co.

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.8.2. Financial Overview

            14.2.8.3. Product Portfolio

            14.2.8.4. SWOT Analysis 

            14.2.8.5. Strategic Overview

        14.2.9. AstraZeneca Plc

            14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.9.2. Financial Overview

            14.2.9.3. Product Portfolio

            14.2.9.4. SWOT Analysis 

            14.2.9.5. Strategic Overview

List of Tables

Table 01: Pipeline Analysis

Table 02: Depression Drugs Sales Analysis, 2015–2017

Table 03: Global Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 04: Global Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 05: Global Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 08: North America Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 09: Europe Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: Europe Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe Schizophrenia drugs  Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 12: Asia Pacific Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Asia Pacific Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 14: Asia Pacific Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 15: Latin America Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 16: Latin America Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 17: Latin America Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 18: Middle East & Africa Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Middle East & Africa Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 20: Middle East & Africa Schizophrenia Drugs  Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

List of Figures

Figure 01: Global Schizophrenia Drugs Market Analysis, by Route of Administration

Figure 02: Global Schizophrenia Drugs Market Analysis, by Drug Class

Figure 03: Global Schizophrenia Drugs Market Analysis, by Region

Figure 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 05: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018

Figure 06: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018

Figure 07: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018

Figure 08: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, 2017–2027

Figure 09: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 10: Global Schizophrenia Drugs Market Revenue (US$ Mn), by First Generation Drugs, 2017–2027

Figure 11: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Second Generation Drugs, 2017–2027

Figure 12: Global Schizophrenia Drugs  Market Revenue (US$ Mn), by Third Generation Drugs, 2017–2027

Figure 13: Global Schizophrenia Drugs  Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 14: Global Schizophrenia Drugs  Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 15: Global Schizophrenia Drugs  Market Revenue (US$ Mn), by Oral Route of Administration, 2017–2027

Figure 16: Global Schizophrenia Drugs  Market Revenue (US$ Mn), by Injectable Route of Administration, 2017–2027

Figure 17: Global Schizophrenia Drugs  Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 18: Global Schizophrenia Drugs  Market Value Share Analysis, by Region, 2018 and 2027

Figure 19: Global Schizophrenia Drugs  Market Attractiveness Analysis, by Region, 2019–2027

Figure 20: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 21: North America Schizophrenia Drugs  Market Attractiveness Analysis, by Country, 2019–2027

Figure 22: North America Schizophrenia Drugs  Market Value Share Analysis, by Country, 2018 and 2027

Figure 23: North America Schizophrenia Drugs  Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 24: North America Schizophrenia Drugs  Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 25: North America Schizophrenia Drugs  Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 26: North America Schizophrenia drugs  Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 27: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 28: Europe Schizophrenia Drugs  Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 29: Europe Schizophrenia Drugs  Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 30: Europe Schizophrenia Drugs  Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 31: Europe Schizophrenia Drugs  Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 32: Europe Schizophrenia Drugs  Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 33: Europe Schizophrenia Drugs  Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 34: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 35: Asia Pacific Schizophrenia Drugs  Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 36: Asia Pacific Schizophrenia Drugs  Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 37: Asia Pacific Schizophrenia Drugs  Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 38: Asia Pacific Schizophrenia Drugs  Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 39: Asia Pacific Schizophrenia Drugs  Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 40: Asia Pacific Schizophrenia Drugs  Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 41: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 42: Latin America Schizophrenia Drugs  Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 43: Latin America Schizophrenia Drugs  Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 44: Latin America Schizophrenia Drugs  Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 45: Latin America Schizophrenia Drugs  Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 46: Latin America Schizophrenia Drugs  Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 47: Latin America Schizophrenia Drugs  Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 48: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 49: Middle East & Africa Schizophrenia Drugs  Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 50: Middle East & Africa Schizophrenia Drugs  Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 51: Middle East & Africa Schizophrenia Drugs  Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 52: Middle East & Africa Schizophrenia Drugs  Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 53: Middle East & Africa Schizophrenia Drugs  Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 54: Middle East & Africa Schizophrenia Drugs  Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 55: Global Schizophrenia drugs  Market Analysis, by Company Ranking, 2018

Figure 56: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 57: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 58: Johnson & Johnson Breakdown of Net Sales, by Region, 2018

Figure 59: Johnson & Johnson Breakdown of Net Sales, by Business Segment, 2018 

Figure 60: Allergan Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 61: Allergan R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018

Figure 62: Allergan Breakdown of Net Sales, by Business Segment (%), 2018

Figure 63: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016–2018

Figure 64: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 65: Otsuka Holdings Co. Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014–2017

Figure 66: Otsuka Holdings Co. Ltd. R&D Spending and Sales & Distribution Spending (US$ Bn) – Company Level, 2016–2017

Figure 67: Otsuka Holdings Co. Ltd. Breakdown of Net Sales, by Region (Company Level), 2017

Figure 68: Otsuka Holdings Co. Ltd. Breakdown of Net Sales (Overall Company Level), 2017

Figure 69: Eli Lily and Company Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2016–2018

Figure 70: Eli Lily and Company Breakdown of Net Sales, by Neuroscience Level, 2018

Figure 71: Eli Lily and Company Breakdown of Net Sales, by Region, 2018

Figure 72: AstraZeneca Plc. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014–2017

Figure 73: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018

Figure 74: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018 (%)

Figure 75: Mayne Pharma Group Limited Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016-2018

Figure 76: Mayne Pharma Group Limited Breakdown of Net Sales (%), by Region, 2018

Figure 77: Sumitomo Dainippon Pharma Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2017

Figure 78: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Business Segment, 2017

Figure 79: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Region, 2017

Figure 80: Vanda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2017

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

455

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved